Print this page
-
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Rectum -
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy.
Protocol: 042201Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE).
Protocol: 072204Principal Investigator:
- Patrick Boland (Rutgers University)
Applicable Disease Sites: Esophagus
Stomach -
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Principal Investigator:
- Malcolm Mattes (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
Larynx -
Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions.
Protocol: 032206Principal Investigator:
- Mahnaz Fatahzadeh DMD (Archived - Rutgers New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx